Daniele Rizzi

833 total citations
15 papers, 184 citations indexed

About

Daniele Rizzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Daniele Rizzi has authored 15 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Daniele Rizzi's work include Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Daniele Rizzi is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Daniele Rizzi collaborates with scholars based in Italy, Austria and Czechia. Daniele Rizzi's co-authors include Evaristo Maiello, Salvatore Pisconti, Francesco Giuliani, Antonio Rinaldi, Fortunato Ciardiello, Antonio Febbraro, Nicola Normanno, Saverio Cinieri, Tiziana Pia Latiano and Anna Maria Rachiglio and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Treatment Reviews.

In The Last Decade

Daniele Rizzi

15 papers receiving 183 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniele Rizzi Italy	5	136	95	90	59	18	15	184
Francesca Daniel Italy	7	123 0.9×	56 0.6×	68 0.8×	59 1.0×	29 1.6×	21	180
A. van de Wouw Netherlands	4	149 1.1×	67 0.7×	38 0.4×	73 1.2×	16 0.9×	8	190
Jane Banerji United Kingdom	7	134 1.0×	64 0.7×	155 1.7×	43 0.7×	17 0.9×	11	204
M. Biglietto Italy	7	117 0.9×	79 0.8×	82 0.9×	57 1.0×	47 2.6×	16	209
Stéphane Jacquot France	4	109 0.8×	34 0.4×	103 1.1×	87 1.5×	11 0.6×	13	185
Carole A. Harris Australia	6	134 1.0×	72 0.8×	50 0.6×	28 0.5×	43 2.4×	21	183
Emerik Österlund Sweden	5	103 0.8×	32 0.3×	64 0.7×	46 0.8×	26 1.4×	14	146
Edith Perez United States	3	122 0.9×	100 1.1×	89 1.0×	43 0.7×	17 0.9×	3	214
Adham Jurdi United States	7	91 0.7×	66 0.7×	116 1.3×	77 1.3×	12 0.7×	39	192
Catherine Leger France	5	216 1.6×	96 1.0×	33 0.4×	77 1.3×	39 2.2×	10	263

Countries citing papers authored by Daniele Rizzi

Since Specialization

Citations

This map shows the geographic impact of Daniele Rizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniele Rizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniele Rizzi more than expected).

Fields of papers citing papers by Daniele Rizzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniele Rizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniele Rizzi. The network helps show where Daniele Rizzi may publish in the future.

Co-authorship network of co-authors of Daniele Rizzi

This figure shows the co-authorship network connecting the top 25 collaborators of Daniele Rizzi. A scholar is included among the top collaborators of Daniele Rizzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniele Rizzi. Daniele Rizzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Orlando, Laura, Vito Lorusso, Francesco Giotta, et al.. (2020). Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). The Breast. 53. 18–22. 15 indexed citations

Maiello, Evaristo, Stefano Cordio, Saverio Cinieri, et al.. (2020). Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802). Clinical Colorectal Cancer. 19(2). 109–115. 12 indexed citations

Cardone, Claudia, Verónica Moreno‐Viedma, Pietro Paolo Vitiello, et al.. (2019). AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC). Annals of Oncology. 30. v37–v38. 1 indexed citations

Morelli, Franco, Francesco Bertoldo, Gaetano Facchini, et al.. (2018). Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study.. Journal of Clinical Oncology. 36(6_suppl). TPS405–TPS405. 1 indexed citations

Cardone, Claudia, Verónica Moreno‐Viedma, Mariel C. Paul, et al.. (2018). AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of Oncology. 29. viii30–viii30. 4 indexed citations

Maiello, Evaristo, Stefano Cordio, Saverio Cinieri, et al.. (2018). Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).. Journal of Clinical Oncology. 36(15_suppl). 3542–3542. 3 indexed citations

Cardone, Claudia, Mariel C. Paul, Verónica Moreno‐Viedma, et al.. (2017). Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Annals of Oncology. 28. v576–v576. 1 indexed citations

Normanno, Nicola, Riziero Esposito Abate, Matilde Lambiase, et al.. (2017). RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Annals of Oncology. 29(1). 112–118. 81 indexed citations

Maiello, Evaristo, Erika Martinelli, Claudia Cardone, et al.. (2016). Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial. Annals of Oncology. 27. iv39–iv39. 4 indexed citations

10.

Galetta, Domenico, Saverio Cinieri, Salvatore Pisconti, et al.. (2014). Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Clinical Lung Cancer. 16(4). 262–273. 50 indexed citations

11.

Orlando, Laura, Francesco Giotta, Daniele Rizzi, et al.. (2013). When less is better: Safety and efficacy of combination of trastuzumab and continuous low oral dose chemotherapy (HEX) as first-line therapy for HER2-positive advanced breast cancer (ABC)—First early results from a phase II trial on behalf of Gruppo Oncologico Italia Meridionale (GOIM).. Journal of Clinical Oncology. 31(15_suppl). 618–618. 2 indexed citations

12.

Galetta, Domenico, Salvatore Pisconti, Saverio Cinieri, et al.. (2013). First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale).. Journal of Clinical Oncology. 31(15_suppl). 8071–8071. 3 indexed citations

13.

Giuliani, Francesco, Antonio Febbraro, Raffaele Addeo, et al.. (2011). Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma (HCC): A phase II study by the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2705).. Journal of Clinical Oncology. 29(4_suppl). 225–225. 3 indexed citations

14.

Giuliani, Francesco, Raffaele Addeo, Daniele Rizzi, et al.. (2010). 4 SORAFENIB PLUS CISPLATIN AND GEMCITABINE IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II STUDY BY THE GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE (PROT. GOIM 2705). Cancer Treatment Reviews. 36. S96–S96. 3 indexed citations

15.

Rizzi, Daniele, et al.. (1971). [Chronic non-hemolytic jaundice with indirect bilirubin (Gilbert's syndrome) with accumulation of pigment in the liver and retention of BSF].. PubMed. 15(1). 77–88. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact